title: Dual antiplatelet therapy for PCI: Are we tailored to all?
authors.affiliation: University of Michigan, Department of Pharmacology, Ann Arbor, MI; University of Michigan, Department of Internal Medicine, Ann Arbor, MI. Electronic address: mholinst@med.umich.edu.
authors.forename: Michael
authors.initials: M
authors.lastname: Holinstat
authors.affiliation: University of Michigan, Department of Pharmacology, Ann Arbor, MI.
authors.forename: Adili
authors.initials: A
authors.lastname: Reheman
mesh_terms: D001241:Aspirin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009206:Myocardium / Q000473:pathology*; D009336:Necrosis / Q000473:pathology*; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D058925:Receptors, Purinergic P2Y12 / Q000737:chemistry*; D013929:Thromboxane B2 / Q000378:metabolism*
chemical_list: D010975:Platelet Aggregation Inhibitors; D058925:Receptors, Purinergic P2Y12; D013929:Thromboxane B2; D001241:Aspirin